Ningbo Biomedical Industry Development Conference
Biomedicine, as one of China's seven strategic emerging industries, is an important foundation for the construction of a Healthy China and a key strategic emerging industry that Ningbo focuses on. To further promote the high-quality and rapid development of the biomedical industry, optimize global clinical development and cross-border cooperation, facilitate the promotion of technological achievements and supply-demand matching, the 'Second China Ningbo Biomedical Industry Development Conference' and the 'Third New Drug Entrepreneurship in Qianwan Project Roadshow'&Investment and Financing Negotiation Meeting" ” was held on2023year12month15 - 17The event is held in Ningbo every day.
at12month16At the main conference venue on the day, academicians and experts, senior executives from pharmaceutical companies, academic luminaries, etc.600More than a hundred people gathered to discuss the current hot topics in the biopharmaceutical industry and to assess the future development direction of the life health industry in Qianwan New Area. Academicians Chen Kaixian, Lin Guoqiang, Zhao Guoping, Ge Junbo, Shi Jianlin from the Chinese Academy of Sciences, and Wu Yuzhang from the Chinese Academy of Engineering participated in the event either online or offline.
The conference focused on innovative drug research and development, cellular and gene therapies,AIDiscussions and exchanges are held on topics such as synthetic biology, small nucleic acid drug research and development, and modernization of traditional Chinese medicine. By deeply integrating industry resources and industrial capital, we jointly promote the vigorous development of the biopharmaceutical industry.
Frost & SullivanFrost & SullivanLi Qian, consulting director of the Life Sciences Business Unit in Greater China at Frost & Sullivan, was invited to attend the conference and participate in the 'Staying Focused, Overcoming Cycles' - Biopharmaceutical Investment and Financing Session, with the theme of “2023A special speech was delivered on the theme of "Insights into the Investment and Financing Trends of Biomedicine in 2023," analyzing the current situation of biomedicine investment and financing and the popular biotech tracks. Li Qian pointed out that popular tracks include gene editing, conjugated drugs, and peptides, which demonstrate broad market prospects.
Academician of the Chinese Academy of Sciences Chen Kaixian
At the beginning of this investment and financing session, Academician Chen Kaixian of the Chinese Academy of Sciences took the stage to deliver a speech and gave a special presentation titled "Biomedical Research and Artificial Intelligence Technology in China," elaborating on the current development status and trends of biomedicine in China. In his report, Academician Chen pointed out the challenges in the development of biomedicine and shared with the guests present the application and importance of artificial intelligence in drug research and development in recent years.
v
Consulting Director, Life Sciences Business Unit, Frost & Sullivan Greater China Region Li Qian
Li Qian, Consulting Director of Life Sciences at Frost & Sullivan Greater China, shared2023Insights into the Investment and Financing Trends in Biomedicine for the Year. She stated that global investment and financing in innovative drugs2022The continuous decline in the year has made it more challenging for capital markets to identify 'hard innovation capability' enterprises, and pharmaceutical companies will also face a more intense competitive environment for funds.
Looking at the investment and financing situation in the innovation field of the capital market, Li Qian pointed out that the number and amount of investment and financing transactions for innovative drugs are2021Peaks are reached annually, reaching608Then it started to fall back,2022In the past year, investment and financing in innovative drugs have slowed down. In terms of investment and financing rounds, a large number of transactions have focused on the early stages.2019Year-end2023In [year], investment in innovative drugs was concentrated inAPrior to this, the proportion was70%left and right; from the perspective of corporate financing,18AlistingTop 5The company existsIPO listingThe total previous financing is higher thanIPO listingThe situation of raised funds, and the Sci-tech Innovation Board5listed companyIPO listingThe raised funds are higher.
Subsequently, Li Qian analyzed three major hot tracks in the biopharmaceutical field, including gene drugs, conjugated drugs, and peptide drugs.
Li Qian pointed out that gene drugs have outstanding clinical value and have been explored for treatment in many disease areas. In recent years, the market launch of gene drugs has accelerated, and the number of research pipelines has expanded rapidly; the market scale of conjugated drugs has maintained high-speed growth, globally and in China.ADCThe indications are currently focused on solid tumors such as breast cancer, and are gradually expanding to non-tumor indications such as autoimmune diseases.ADCThe technologies of each component are continuously iterated toRDC/PDCThe new type of conjugated drug represented by it has unique advantages and is expected to become a new driving force for market growth; after the launch of Simeprevir Dipivoxil Injection in China, there has been a shortage.GLP1RThe high growth rate of the targeted peptide drug market has driven rapid growth in the peptide drug market. As the application areas of peptide drugs continue to expand,GLP1RPeptide drugs are making significant progress, and their indications will undergo a major transformation after being extended to weight loss, further opening up market space.
More wonderful moments from forums
About Frost & Sullivan's Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life sciences industry. The Life Sciences Practice has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, accumulating extensive project experience in various subfields of life sciences.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized sub-sectors such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
